Melanie Cree-Green1,2, Bryan C Bergman3, Gregory V Coe4, Lindsey Newnes4, Amy D Baumgartner4, Samantha Bacon3, Ann Sherzinger5, Laura Pyle6,7, Kristen J Nadeau4,8. 1. Department of Pediatrics, Division of Pediatric Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. melanie.green@childrenscolorado.org. 2. Department of Pediatric Endocrinology, Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. melanie.green@childrenscolorado.org. 3. Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 4. Department of Pediatrics, Division of Pediatric Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 5. Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 6. Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 7. Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA. 8. Department of Pediatric Endocrinology, Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
OBJECTIVE: Increased liver fat and type 2 diabetes are prevalent in women with polycystic ovarian syndrome (PCOS) and cause excess mortality, yet little is known about their development during adolescence. The objective of this study was to measure hepatic steatosis and related metabolic contributors in girls with obesity, with and without PCOS. METHODS: Nondiabetic adolescents with obesity, 41 with PCOS (PCOS; age 15.0 [13.0-16.0] years, BMI 35.2 ± 0.61 kg/m2 ) and 30 without PCOS (OB; age 14.5 [13.0-17.0], BMI 33.2 ± 1.8), were studied. Visceral and liver fat were assessed with MRI. Serum measures included androgens and 16:1 and 18:1 N7 fatty acids specific to de novo lipogenesis. Adipose, hepatic, and peripheral insulin sensitivity (IS) were assessed with a four-phase hyperinsulinemic-euglycemic clamp with isotope tracers. RESULTS: Forty-nine percent of the PCOS group had hepatic steatosis versus fourteen percent of the OB group (P = 0.02), and the PCOS group had higher N7 (43 ± 4 vs. 29 ± 5 nmol/g; P = 0.02). Peripheral IS was lower in PCOS (9.4 [7.2-12.3] vs. 14.5 [13.1-18.05 mg/lean kg/min]; P < 0.001) as was hepatic (P = 0.006) and adipose IS (P = 0.005). Percent liver fat correlated with N7 (R = 0.46, P = 0.02) and visceral fat (R = 0.42, P < 0.001), not androgens or peripheral IS. CONCLUSIONS: Nearly 50% of nondiabetic girls with PCOS and obesity have hepatic steatosis, which relates to visceral fat and lipogenesis, but not to IS or androgens.
OBJECTIVE: Increased liver fat and type 2 diabetes are prevalent in women with polycystic ovarian syndrome (PCOS) and cause excess mortality, yet little is known about their development during adolescence. The objective of this study was to measure hepatic steatosis and related metabolic contributors in girls with obesity, with and without PCOS. METHODS:Nondiabetic adolescents with obesity, 41 with PCOS (PCOS; age 15.0 [13.0-16.0] years, BMI 35.2 ± 0.61 kg/m2 ) and 30 without PCOS (OB; age 14.5 [13.0-17.0], BMI 33.2 ± 1.8), were studied. Visceral and liver fat were assessed with MRI. Serum measures included androgens and 16:1 and 18:1 N7 fatty acids specific to de novo lipogenesis. Adipose, hepatic, and peripheral insulin sensitivity (IS) were assessed with a four-phase hyperinsulinemic-euglycemic clamp with isotope tracers. RESULTS: Forty-nine percent of the PCOS group had hepatic steatosis versus fourteen percent of the OB group (P = 0.02), and the PCOS group had higher N7 (43 ± 4 vs. 29 ± 5 nmol/g; P = 0.02). Peripheral IS was lower in PCOS (9.4 [7.2-12.3] vs. 14.5 [13.1-18.05 mg/lean kg/min]; P < 0.001) as was hepatic (P = 0.006) and adipose IS (P = 0.005). Percent liver fat correlated with N7 (R = 0.46, P = 0.02) and visceral fat (R = 0.42, P < 0.001), not androgens or peripheral IS. CONCLUSIONS: Nearly 50% of nondiabetic girls with PCOS and obesity have hepatic steatosis, which relates to visceral fat and lipogenesis, but not to IS or androgens.
Authors: Christopher R McCartney; Susan K Blank; Kathleen A Prendergast; Sandhya Chhabra; Christine A Eagleson; Kristin D Helm; Richard Yoo; R Jeffrey Chang; Carol M Foster; Sonia Caprio; John C Marshall Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Mark R Palmert; Catherine M Gordon; Alex I Kartashov; Richard S Legro; S Jean Emans; Andrea Dunaif Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958
Authors: Melanie Cree-Green; Bradley R Newcomer; Gregory Coe; Lindsey Newnes; Amy Baumgartner; Mark S Brown; Laura Pyle; Jane E Reusch; Kristen J Nadeau Journal: Am J Physiol Endocrinol Metab Date: 2015-02-24 Impact factor: 4.310
Authors: Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: Maya Gambarin-Gelwan; Sanjiv V Kinkhabwala; Thomas D Schiano; Carol Bodian; Hsu-Chong Yeh; Walter Futterweit Journal: Clin Gastroenterol Hepatol Date: 2007-02-06 Impact factor: 11.382
Authors: Melanie Cree-Green; Bryan C Bergman; Eda Cengiz; Larry A Fox; Tamara S Hannon; Kellee Miller; Brandon Nathan; Laura Pyle; Darcy Kahn; Michael Tansey; Eileen Tichy; Eva Tsalikian; Ingrid Libman; Kristen J Nadeau Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958
Authors: Camila F Pereira-Eshraghi; Codruta Chiuzan; Yuan Zhang; Rachel H Tao; Matthew McCann; Y Dana Neugut; Alison Printz; Ilene Fennoy; Melanie Cree-Green; Sharon E Oberfield; Aviva B Sopher Journal: Horm Res Paediatr Date: 2020-04-29 Impact factor: 2.852